LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that on June 6, 2008 it will present study data indicating that diabetic mice treated with iroxanadine healed from diabetic wounds nearly two times faster than untreated diabetic mice. These study results will be introduced by CytRx’s Senior Vice President of Research and Development Shi Chung Ng, Ph.D., at the Third Congress of the World Union of Wound Healing Societies held in Toronto, Canada.
